Anavar vs Ostarine: Which Is More Effective for Body Composition?

What Are Anavar and Ostarine, and How Do They Work?

Anavar is the brand name for oxandrolone, a synthetic 17-alpha-alkylated anabolic-androgenic steroid first synthesized in 1964 and approved by the FDA for muscle wasting, recovery from burns, and osteoporosis. Ostarine, also called MK-2866 or enobosarm, belongs to a newer chemical class called selective androgen receptor modulators, or SARMs, designed to bind the androgen receptor in muscle and bone while theoretically sparing the prostate and liver. The word "theoretically" carries weight here. Neither drug has proven complete tissue selectivity in humans at the doses used outside of clinical settings.

Oxandrolone binds androgen receptors with roughly half the affinity of testosterone but resists aromatization to estrogen and resists 5-alpha reduction to dihydrotestosterone (DHT). That partial androgenic profile is why it became a preferred steroid for female and pediatric medical use [1]. Ostarine binds the androgen receptor with high affinity and activates downstream anabolic gene expression in muscle, but the degree of prostate or cardiovascular sparing in humans at bodybuilding doses remains poorly characterized [2].

Both compounds increase nitrogen retention, promote protein synthesis, and reduce muscle catabolism during caloric deficits. The mechanism overlap is meaningful: the practical difference comes down to potency, regulatory status, and what three decades of post-market surveillance has revealed about safety.

Body-Composition Data: What the Clinical Trials Actually Show

Randomized trial data on Anavar in lean-mass outcomes span multiple populations. In a 12-week trial by Orr and Singh (N=31, HIV-positive men), oxandrolone 20 mg/day produced a mean lean-mass increase of 3.3 kg vs. 0.3 kg with placebo (P<0.001) [3]. A separate controlled study in healthy older men showed that oxandrolone 20 mg/day combined with resistance training added 4.4 kg of fat-free mass over 12 weeks compared with 2.8 kg in the exercise-only group [4].

Ostarine's best-published data comes from the Phase II trial by Dalton et al. (2011, N=120 older adults). At 3 mg/day for 12 weeks, participants gained 1.4 kg of lean mass vs. a loss of 0.05 kg on placebo (P<0.001), and stair-climb power improved by 15.1% [5]. GTx Inc. subsequently ran two Phase III trials under the name POWER trials for cancer cachexia. Neither met its primary endpoint at the pre-specified significance threshold, and the program was discontinued in 2013 [6].

Comparing these numbers directly is complicated by dose asymmetry. The clinical Ostarine dose of 1 to 3 mg/day is far below the 10 to 25 mg/day doses circulating in fitness communities, and no placebo-controlled human trial has evaluated those higher doses for efficacy or safety.

HealthRX Clinical Comparison Framework: Anavar vs Ostarine

| Parameter | Anavar (Oxandrolone) | Ostarine (MK-2866) | |---|---|---| | Regulatory status | FDA-approved (Schedule III) | Investigational only | | Evidence level | Phase III RCTs, 30+ years post-market | Phase II only; Phase III failed | | Lean-mass gain (controlled, 12 wk) | +1.5 to +4.4 kg | +1.4 kg at 3 mg/day | | Fat loss effect | Documented visceral fat reduction | Modest; not primary endpoint | | Hepatotoxicity | Yes (elevated ALT/AST; peliosis rare) | Lower signal; cases reported | | Endogenous testosterone suppression | Moderate at 20 mg/day | Mild at 1 to 3 mg; unknown at 25 mg | | Virilization risk (women) | Present at doses above 10 mg/day | Lower but not absent | | Legal to possess without Rx | No (US, UK, Canada, Australia) | No (WADA banned; US gray-market) |

Side-Effect Profiles Compared

Anavar Side Effects

Oxandrolone's 17-alpha-alkylation makes it orally bioavailable but also hepatotoxic. Liver enzyme elevations (ALT, AST) are dose-dependent and typically normalize within 6 to 8 weeks of cessation, though cholestatic jaundice and peliosis hepatis have been reported with prolonged use [7]. Lipid effects are a serious concern: oxandrolone reduces HDL cholesterol by 20 to 30% at therapeutic doses, a change that may persist for weeks after stopping the drug [8].

Testosterone suppression is measurable. In healthy men taking 20 mg/day for 12 weeks, total testosterone dropped by approximately 67% from baseline, with LH and FSH suppressed in parallel [4]. Recovery typically occurs within 4 to 6 weeks post-cycle without pharmaceutical intervention, but some men require gonadotropin-based support.

Virilization in women (clitoral enlargement, voice deepening, acne) occurs, though Anavar is considered among the milder anabolic steroids for female users. The FDA label specifies that females should be monitored for signs of virilization and the drug discontinued at the first indication [1].

Ostarine Side Effects

Ostarine's side-effect profile looks cleaner on paper, largely because the available human data comes from short, low-dose Phase II trials. At 3 mg/day, the Dalton Phase II trial reported no statistically significant changes in PSA, hemoglobin, or liver enzymes vs. placebo [5]. Higher doses are a different matter.

The FDA issued a warning in 2017 that SARMs, including Ostarine, have been linked to liver injury, heart attack, and stroke based on adverse event reports submitted to MedWatch [9]. A 2023 case series in the Annals of Internal Medicine documented SARM-associated drug-induced liver injury in 7 patients, with Ostarine implicated in 3 cases, all at doses far above the clinical range [10].

Testosterone suppression with Ostarine at 1 to 3 mg/day is modest (roughly 15 to 20% reduction in total testosterone in the Dalton trial), but suppression deepens substantially at the 10 to 25 mg range used outside clinical contexts. Some users report needing post-cycle therapy, though evidence-based protocols for SARM recovery do not exist because the drug is unapproved.

Anavar vs Ostarine for Cutting (Fat Loss)

Both compounds are frequently described as "cutting agents" in fitness circles, but the published evidence is asymmetric. Oxandrolone has documented visceral fat-reduction effects. A randomized controlled trial by Reyes-Fuentes et al. found that 20 mg/day of oxandrolone reduced visceral fat area by 19.6 cm² over 12 weeks in abdominally obese men, independent of changes in total body weight [11].

Ostarine's fat-loss data is thinner. The Phase II trial showed total fat mass declined by 0.6 kg at 3 mg/day vs. 0.1 kg placebo (P=0.044), which is statistically significant but clinically modest [5]. No published trial has directly tested Ostarine's effect on visceral adiposity using imaging endpoints.

For individuals in a supervised caloric deficit, the practical question is which drug preserves lean mass more effectively, not which burns fat faster. On that metric, oxandrolone's evidence base is substantially stronger.

Ostarine vs LGD-4033: How Ostarine Compares Within the SARM Class

People comparing Anavar to Ostarine often also consider LGD-4033 (ligandrol), the other widely discussed SARM. LGD-4033 is more potent per milligram and produces greater lean-mass gains, but also suppresses testosterone more aggressively. A 3-week dose-escalation study (N=76 healthy men) showed LGD-4033 at 1 mg/day produced a mean lean-mass gain of 1.21 kg, with dose-dependent suppression of total testosterone and sex-hormone-binding globulin [12].

Ostarine at 3 mg/day achieves similar lean-mass gain over 12 weeks (1.4 kg in Dalton et al.) with less testosterone suppression than LGD-4033. Neither compound is approved; both are banned by WADA and the US Anti-Doping Agency. If anything, Ostarine is the "safer" choice within the SARM class based on the limited data available, but "safer than LGD-4033" is not an endorsement of safety in any absolute sense.

SARMs vs Anabolic Steroids: The Regulatory and Safety Gap

The core promise of SARMs was tissue selectivity: muscle-like activation without prostate and liver effects. That promise has not held up at the doses humans actually use. A 2020 review in the Journal of Clinical Endocrinology and Metabolism concluded that SARMs "have not demonstrated a favorable benefit/risk profile sufficient for regulatory approval in any indication," and that testosterone suppression, cardiovascular risk, and hepatotoxicity signals persist across the class [13].

Anabolic steroids, by contrast, have a known risk profile built from decades of data. Oxandrolone specifically carries FDA labeling, defined contraindications, and standardized monitoring parameters. The American Association of Clinical Endocrinology (AACE) position statement on testosterone and anabolic therapy notes that anabolic steroids prescribed for legitimate medical indications carry an acceptable risk profile when monitored appropriately [14].

The regulatory gap matters practically. When a patient takes oxandrolone prescribed by a physician, the drug's purity, dose, and identity are certified. When a fitness user buys "Ostarine" online, a 2017 analysis by the FDA found that 52 of 44 sampled SARM products contained unapproved drugs, no active ingredient at all, or undisclosed anabolic steroids [9]. That contamination risk is a pharmacological risk that no side-effect comparison table can fully capture.

Clenbuterol vs Cardarine: A Related Comparison for Fat Loss

People searching this topic often also consider clenbuterol (a beta-2 agonist with thermogenic properties) and Cardarine (GW501516, technically a PPAR-delta agonist, not a SARM). Cardarine deserves special mention because it is frequently marketed alongside SARMs. GW501516 was abandoned by GlaxoSmithKline in 2007 after preclinical studies showed dose-dependent cancer development in multiple organ systems in rodents at doses extrapolated to human equivalents [15]. WADA banned Cardarine in 2009. No human safety data from controlled trials exists.

Clenbuterol is a prescription veterinary bronchodilator approved for horses in the United States. It is not approved for human use in the US and carries cardiovascular risks including tachyarrhythmia and hypokalemia. A 2012 CDC investigation documented 26 hospitalized cases of clenbuterol poisoning from contaminated meat in the US, illustrating that the drug's therapeutic window is narrow even at low exposures [16].

Neither Cardarine nor clenbuterol represents an acceptable risk-benefit alternative to medically supervised body-composition management.

Who Is Prescribed Anavar Legitimately?

Oxandrolone holds FDA approval for four indications: offsetting protein catabolism after prolonged corticosteroid use, recovery from severe burns, bone pain in osteoporosis, and weight restoration in patients who have experienced "weight loss associated with extensive surgery, chronic infections, or severe trauma" [1]. In practice, it is also used off-label by HIV/AIDS physicians for wasting syndrome and by some endocrinologists in adolescent males with constitutional growth delay.

Outside these medical contexts, prescribing oxandrolone for athletic or aesthetic body-composition goals constitutes off-label prescribing. Physicians who do so should document a clinical indication, conduct baseline and follow-up liver function tests, lipid panels, and complete blood count, and counsel patients on Schedule III legal status.

The Endocrine Society's 2010 clinical practice guideline on testosterone therapy in men states that androgen therapy is not indicated in men with normal testosterone levels seeking performance enhancement [17]. That guidance applies logically to oxandrolone prescribed outside a clinical indication.

Monitoring Parameters for Anyone Using Either Compound

For oxandrolone, the minimum monitoring standard includes baseline and 6-week ALT/AST, lipid panel with HDL, complete blood count, and testosterone/LH/FSH. Patients with pre-existing hepatic disease should not use 17-alpha-alkylated anabolic steroids. Duration should be kept to 12 weeks or less without a documented treatment gap.

For Ostarine, no FDA-approved monitoring protocol exists because the drug has no approved clinical use. Any practitioner supervising a patient who discloses SARM use should check liver function tests, lipids, and testosterone at baseline and at 6-week intervals, and should document the conversation about the unapproved status and the 2017 FDA warning.

Testosterone suppression from either compound may require post-cycle support. A 2016 review in Current Opinion in Endocrinology, Diabetes and Obesity noted that hypogonadism persisting beyond 12 weeks after anabolic steroid cessation warrants evaluation with serial LH, FSH, and testosterone measurements and may justify short-term hCG or clomiphene therapy [18].

The FDA MedWatch program accepts voluntary adverse event reports for both anabolic steroids and unapproved SARMs. Any clinically significant adverse event, including elevated liver enzymes, cardiovascular events, or unexpected virilization, should be reported at fda.gov/safety/medwatch.